Hypoglycemia with Mealtime Fast-Acting Insulin Aspart vs. Insulin Aspart Across Two Large Type 1 Diabetes Trials

被引:10
|
作者
De Block, Christophe
Carlson, Anders
Rose, Ludger
Gondolf, Theis
Gorst-Rasmussen, Anders
Lane, Wendy
机构
关键词
D O I
10.2337/db18-96-LB
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial
    Komatsu, Mitsuhisa
    Ekelund, Magnus
    Horio, Hiroshi
    Kadowaki, Takashi
    ENDOCRINE JOURNAL, 2021, 68 (04) : 429 - 440
  • [32] Use of fast-acting insulin aspart in insulin pump therapy in clinical practice
    Evans, Mark
    Ceriello, Antonio
    Danne, Thomas
    De Block, Christophe
    DeVries, J. Hans
    Lind, Marcus
    Mathieu, Chantal
    Norgaard, Kirsten
    Renard, Eric
    Wilmot, Emma G.
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2039 - 2047
  • [33] Insulin aspart - A mealtime alternative to soluble human insulin in type 1 diabetes.
    Hoogwerf, B
    Raskin, P
    Jovanovic, L
    Leiter, L
    Boss, AH
    Riis, A
    DIABETOLOGIA, 1999, 42 : A237 - A237
  • [34] A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes
    Beck, Roy W.
    Russell, Steven J.
    Damiano, Edward R.
    El-Khatib, Firas H.
    Ruedy, Katrina J.
    Balliro, Courtney
    Li, Zoey
    Calhoun, Peter
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (10) : 681 - 696
  • [35] Faster-Acting Insulin Aspart Improves Postprandial Glycemia vs. Insulin Aspart in Patients with Type 1 Diabetes Mellitus (T1DM)
    Heise, Tim
    Haahr, Hanne L.
    Jensen, Lene
    Erichsen, Lars
    Hompesch, Marcus
    DIABETES, 2014, 63 : A34 - A34
  • [36] A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
    Tim Heise
    Thomas R. Pieber
    Thomas Danne
    Lars Erichsen
    Hanne Haahr
    Clinical Pharmacokinetics, 2017, 56 : 551 - 559
  • [37] Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart
    Pieber, Thomas R.
    Svehlikova, Eva
    Brunner, Martina
    Halberg, Inge B.
    Thomsen, Karen Margrete Due
    Haahr, Hanne
    DIABETES OBESITY & METABOLISM, 2019, 21 (09): : 2068 - 2075
  • [38] Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart
    Pieber, T. R.
    Basu, A.
    Hansen, A. K.
    Sach-Friedl, S.
    Thomsen, K. M. D.
    Basu, R.
    Haahr, H.
    DIABETOLOGIA, 2017, 60 : S315 - S315
  • [39] A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
    Heise, Tim
    Pieber, Thomas R.
    Danne, Thomas
    Erichsen, Lars
    Haahr, Hanne
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 551 - 559
  • [40] THE IMPACT OF BASELINE BMI AND HBA1C ON GLYCAEMIC CONTROL AFTER TREATMENT WITH MEALTIME FAST-ACTING INSULIN ASPART IN PEOPLE WITH TYPE 1 DIABETES
    Russell-Jones, D.
    Heller, S.
    Woo, V.
    Babu, V.
    Dethlefsen, C.
    Mathieu, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A136 - A137